WNT5A and breast cancer: Their data provided proof of principle that reconstitution of WNT5a signalling represents a valid approach to impair BC metastasis, and the compound is now under evaluation in a clinical Phase I study to establish the recommended dose for a clinical phase II study and enable further development of Foxy-5 as a first-in-class anti-metastatic cancer drug.